Pyrazole derivatives and their medical use

Details for Australian Patent Application No. 2006313478 (hide)

Owner Pfizer Limited

Inventors Johnson, Patrick Stephen; Bradley, Paul Anthony; Skerratt, Sarah Elizabeth; Dack, Kevin Neil

Agent Allens Arthur Robinson

Pub. Number AU-A-2006313478

PCT Pub. Number WO2007/054770

Priority 60/735,091 08.11.05 US

Filing date 26 October 2006

Wipo publication date 18 May 2007

International Classifications

C07D 231/18 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

A61K 31/415 (2006.01) - 1,2-Diazoles

A61P 15/00 (2006.01) Drugs for genital or sexual disorders

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

8 May 2008 PCT application entered the National Phase

  PCT publication WO2007/054770 Priority application(s): WO2007/054770

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006313486-Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as PDE5 inhibitors

2006313464-Method of converting water-soluble active proteins into hydrophobic active proteins, the use of the same for the preparation of monomolecular layers of oriented active proteins, and devices comprising the same